IGC Pharma Inc (A:IGC)

Business Focus: Biotechnology & Medical Research

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 2405 York Road, Suite 201
LUTHERVILLE-TIMONIUM MD 21093-2264
Tel: N/A
Website: https://igcpharma.com
IR: See website
<
Key People
Ram Mukunda
President, Chief Executive Officer, Director
Claudia Grimaldi
Vice-President, Principal Financial Officer, Chief Compliance Officer, Director
 
Business Overview
IGC Pharma, Inc. is a clinical-stage pharmaceutical company. It develops advanced cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. Its segments include Life Sciences and Infrastructure. It has two investigational drug assets targeting Alzheimer's disease, IGC-AD1 and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles. IGC-AD1 is a low-dose tetrahydrocannabinol (THC) based formulation that is in a 146-person phase II clinical trial for agitation in dementia due to Alzheimer's. TGR-63, a non-cannabinoid molecule, is an enzyme inhibitor shown in pre-clinical trials to reduce neurotoxicity in Alzheimer's cell lines. It also markets a wellness brand, Holief, that targets women experiencing premenstrual syndrome and menstrual cramps.
Financial Overview
For the nine months ended 31 December 2023, IGC Pharma Inc revenues increased 41% to $1.1M. Net loss increased 35% to $10.1M. Revenues reflect Life Sciences segment increase of 29% to $883K, Infrastructure segment increase from $59K to $167K, U.S. segment increase of 31% to $883K, India segment increase from $59K to $167K. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.14 to -$0.17.
Employees: 61 as of Mar 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $25.62M as of Dec 31, 2023
Annual revenue (TTM): $1.22M as of Dec 31, 2023
EBITDA (TTM): -$9.92M as of Dec 31, 2023
Net annual income (TTM): -$14.15M as of Dec 31, 2023
Free cash flow (TTM): -$6.86M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 66,062,775 as of Mar 19, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.